NEW YORK, April 16 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats, provided an update covering its strategic and drug development activities for the period of 2006 and first quarter of 2007.
